Discover a world of possibilities
For academic clients, we typically use CRISPR-based approaches, as researchers usually have no intention of commercialising the resulting cells, and CRISPR offers speed, precision, and flexibility.
For industry clients who plan to sell edited cells or cell-derived products, we offer a specialised service that delivers fully edited, royalty-free cell lines. This is ideal if your goal is commercialization: CRISPR-based editing, while powerful, is covered by recent and heavily litigated patents, creating long-term uncertainty and potential licensing burdens. To eliminate these risks, we have developed a workflow and new synthetic plasmids based entirely on off-patent technologies.
The off-patent technology we use for company clients was originally developed in the 1980s and 1990s and was instrumental for the revolution in murine genetics that ultimately led to a Nobel Prize. Although more technically demanding than modern nuclease-based systems like CRISPR–Cas9, these methods produce edited cell lines that are equivalent or even superior in quality, while remaining entirely free of patent restrictions.
Nucleica - Investigação e Engenharia Genética 